Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma's stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent "Best New Product" award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS) through their wholly owned subsidiary, ReceptoPharm Inc. With billions of dollars in potential target markets, Nutra Pharma is one company which is ready to take the biopharmaceuticals sector by storm.

About

Nutra Pharma Corp. is a development-stage biopharmaceutical company engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The Company's wholly owned subsidiary, ReceptoPharm, Inc. (Recepto Pharm) is a development stage biopharmaceutical company, which is engaged in developing technologies to treat the neurological diseases: multiple sclerosis; adrenomyeloneuropathy; amyotrophic lateral sclerosis; myasthenia gravis; and to treat the viral diseases, human immunodeficiency virus (HIV) and hepatitis-C. The Company's other wholly owned subsidiary Designer Diagnostics, Inc. (Designer Diagnostics) is engaged in marketing diagnostic test kits that are used for the rapid identification of infectious human diseases, such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

Midterm goal

Nutra Pharma Corp's midterm strategy for the past three years has been to license Nutra Pharma Corp's AMN, MS and HIV technologies in Nutra Pharma Corp's attempt to bring these technologies to market within 5 years. Should Nutra Pharma Corp. obtain adequate financing, Nutra Pharma Corp's midterm strategy remains the same— to accomplish these midterm goals in the next two years of that 5 year period.

Long-term goal

Nutra Pharma Corp's long-term goal is the use of drugs developed by ReceptoPharm and future affiliates in the field of neurological diseases, infectious diseases and autoimmune disorders. Due to Nutra Pharma Corp's limited financial and operational resources, this goal will require Nutra Pharma Corp. to establish strategic partners or alliances with pharmaceutical companies, academic institutions, biotechnology companies, and clinical diagnostic laboratories, which will: (a) complement Nutra Pharma Corp's research and development efforts; (b) reduce the risks associated with undertaking the entire process of drug development and marketing; and (c) generate licensing based revenue streams.

Potential Revenue Segments

Nutra Pharma Corp's potential revenue segments are composed of Nutra Pharma Corp's attempt to generate revenues from license agreements, joint ventures, drug, and test kit sales with pharmaceutical companies, biotechnology companies and clinical diagnostic laboratories that generate license fees, as follows:

• License revenues developed through licensing agreements
• Joint venture revenues developed through joint venture in foreign countries that will permit local clinical trials and regulatory approval outside the United States
• Drug sales should Nutra Pharma Corp. be successful in obtaining FDA approval
• Test kit sales sold through Designer Diagnostics, Inc.

Products

Cobroxin

By far, the company's most prized product to date. Cobroxin is the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain.